A LOSE-LOSE SITUATION?
Chinese biopharma firms listed in U.S. SEC audit crisis
By Kristine Yang
Wednesday, February 26, 2014
HONG KONG – A recent ruling by the U.S. SEC banning Big Four accounting firms from performing audits linked to China could spell trouble for Chinese biopharmaceutical companies listed in the U.S. The ban is not yet in force pending an appeal.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.